Global Anticoagulants

Market Outlook to 2020

Demand for Patented NOACs with Prevalence of
Cardiac Diseases to Drive Global Market

COMPINES
PRODUCTS MENTIONED
MENTIONED
Xarelto Pfizer, Inc, Sanofi, Boehringer
Eliquis Ingelheim, Bayer AG, Bristol-
Lixiana/Savaysa Myers Squibb Company, Daichi
Pradaxa Sankyo Company Limited, Janssen
Lovenox Pharmaceuticals
Arixtra
Fragmin
Warfarin
 1. Executive Summary
Market Potential
Market Segmentation
Competitive Landscape
Future Outlook and Projections
2. Research Methodology
2.1. Market Definitions
2.2. Abbreviations
Table of Content
2.3. Market Size and Modeling
Approach Market Sizing
Limitations
3. Introduction to Anticoagulants
Uses
Side Effects of Anticoagulants
4. Value Chain Analysis of Global Anticoagulants Market
5. Global Anticoagulants Market Size, 2013 - 2015
6. Global Anticoagulants Market Segmentation
6.1. By Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors), 2015
6.1.1. Heparin Market Segmentation by Type (Unfractionated and Low Molecular
Weight Heparin)
6.1.2. NOACs Market Segmentation by Type (Rivaroxaban, Apixaban, Dabigatran
Etexilate, and Edoxaban)
Drug Approval Timelines
Patent Expiries
6.2. By Route of Administration (Oral and Injectables)
6.3. By Geographical Regions (North America, Europe, Asia Pacific, and Rest of the
World)
7. Snapshot on North America Anticoagulants Market
By Countries (US and Canada)
7.1. US Market Indicators
7.1.1. US Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable
Direct Inhibitors)
7.1.2. Key Anticoagulants in US
7.1.3. Regulatory Landscape
New Drug Approval Procedure
New Drug Timeline
Generic Drug Approval Procedure
Patents
Exclusivity
Anticoagulants Reimbursement Scenario in the US
7.2. Canada Market Indicators
7.2.1. Canada Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable
Direct Inhibitors)
7.2.2. Cost of Key Anticoagulants in Canada
7.2.1. Market Share of Major Players (Bayer Inc., Boehringer Ingelheim, and Bristol
Myers Squibb Canada Co) in Canada Anticoagulants Market, 2015
7.2.2. Regulatory Landscape
Generic Drug Approval Procedure
Patents and Exclusivity
 Pharmaceutical Pricing and Reimbursement in Canada
8. Snapshot on Europe Anticoagulants Market
8.1. By Countries (Germany, France, Spain, Italy, UK, and Rest of the Europe)
8.2. Europe Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable
Direct Inhibitors)
8.2.1. Cost of Key Anticoagulants in Europe
8.3. Europe Anticoagulants Market by Companies (Bayer Inc., Boehringer Ingelheim,
Pfizer, and Others)
Table of Content
8.4. Regulatory Landscape
8.4.1. New Drug Approval Procedure
8.4.2. Patents
8.4.3. Reimbursement Scenario in Europe
9. Snapshot on Asia Pacific Anticoagulants Market
By Countries (Japan, Australia, China, India, and Rest of the Asia Pacific)
9.1. Japan Market Indicators
9.1.1. Japan Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable
Direct Inhibitors)
9.1.2. Key Anticoagulants in Japan
9.1.3. Regulatory Landscape
New Drug Approval Procedure
Patents
9.2. Australia Market Indicators
9.2.1. Australia Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable
Direct Inhibitors)
9.2.2. Cost of Key Anticoagulants in Australia
9.2.3. Regulatory Landscape
New Drug Approval Procedure
Patents
Reimbursement Scenario in Australia
9.3. China Market Indicators
9.3.1. China Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable
Direct Inhibitors)
9.3.2. Cost of Key Anticoagulants in China
9.3.3. Market Share of Major Players (Bayer China, Boehringer Ingelheim, and Others)
in China Anticoagulants Market, 2015
9.3.4. Regulatory Landscape
New Drug Approval Procedure
Patents
9.4. India Market Indicators
9.4.1. India Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable
Direct Inhibitors)
9.4.1. Cost of Key Anticoagulants in India
9.4.2. Market Share of Major Players (Bayer India, Boehringer Ingelheim, Pfizer, GSK
Pharmaceutical Ltd., Aventis Pharma and Others) in India Anticoagulants
Market
9.4.3. Regulatory Landscape
New Drug Approval Procedure
Patents
Pricing and Reimbursement Scenario in India
 10. Porters Five Forces Analysis for Global Anticoagulants Market
11. Trends and Developments in Global Anticoagulants Market
11.1. Expanding Therapeutic Indication
11.2. High incidence rate of DVT/PE
11.3. Disadvantages of Patented NOACs over Generic VKAs and Heparin Impacting
Market Negatively
12. Global Anticoagulants Market Competitive Landscape
12.1. Market Share of Key Players in Global Anticoagulants Market, 2015
Table of Content
12.2. Company Profiles for Key Manufacturers in Anticoagulants Market
12.2.1. Sanofi
12.2.2. Pfizer Inc.
12.2.3. Boehringer Ingelheim
12.2.4. Bayer AG
12.2.5. Bristol-Myers Squibb Company
12.2.6. Daichi Sankyo company, Limited
13. Future of Global Anticoagulants Market
13.1. Future Outlook and Projections, 2016 2020
14. Analyst Recommendations
15. Macroeconomic Indicators
15.1. Aging Population
15.2. Deaths from Cardiovascular Diseases, 2010 - 2020
15.3. Healthcare Spending, 2010 - 2020
Disclaimer
Contact Us
 Figure 4-1: Value Chain Analysis of Global Anticoagulants Market
Figure 5-1: Global Anticoagulants Market on the basis of Revenue in USD Million, 2013
2015
Figure 6-1: Global Anticoagulants Market Segmentation by Type (Heparin, Novel Oral
Anticoagulants, Vitamin K Antagonists, and Injectable Direct Inhibitors) on the basis of
Revenue in Percentage, 2013 - 2015
LIST OF FIGURES
Figure 6-2: Global Heparin Market Segmentation by Type (Unfractionated and Low Molecular
Weight Heparin) on the basis of Revenue in Percentage, 2013 - 2015
Figure 6-3: Global NOACs Market Segmentation by Type (Rivaroxaban, Apixaban,
Dabigatran Etexilate, and Edoxaban) on the basis of Revenue in Percentage, 2013 - 2015
Figure 6-4: Global Anticoagulants Market Segmentation by Route of Administration (Oral
and Injectable) on the basis of Revenue in Percentage, 2013 - 2015
Figure 6-5: Global Anticoagulants Market Segmentation by Geographical Regions (North
America, Europe, Asia Pacific and Rest of the World) on the basis of Revenue in Percentage,
2013 - 2015
Figure 7-1: North America Anticoagulants Market on the basis of Revenue in USD Million,
2013 2015
Figure 7-2: North America Anticoagulants Market Segmentation by Countries (US and
Canada) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 7-3: US Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and
Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 7-4: New Drug Approval Procedure in the US
Figure 7-5: New Drug Timeline in the US
Figure 7-6: ANDA Application Procedure for Generic Drug Approval in the US
Figure 7-7: Para IV Challenge against ANDA Paragraph IV Certification in the US
Figure 7-8: Patent Approval Procedure in the US
Figure 7-9: Canada Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs,
and Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 7-10: Drug Approval Procedure in Canada
Figure 8-1: Europe Anticoagulants Market on the basis of Revenue in USD Million, 2013
2015
Figure 8-2: Europe Anticoagulants Market Segmentation by Countries (Germany, France,
Spain, Italy, UK, and Rest of the Europe) on the basis of Revenue in terms of Percentage,
2013 - 2015
Figure 8-3: Europe Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs,
and Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 8-4: Centralized Procedure for Drug Approval in Europe
Figure 8-5: Mutual Recognition Procedure for Drug Approval in Europe
Figure 8-6: Decentralized Procedure for Drug Approval in Europe
Figure 8-7: Patent Approval Procedure in Europe
Figure 9-1: Asia Pacific Anticoagulants Market on the basis of Revenue in USD Million, 2013
 2015
Figure 9-2: Asia Pacific Anticoagulants Market Segmentation by Countries (Japan, Australia,
China, India, and Rest of the Asia Pacific) on the basis of Revenue in terms of Percentage,
2013 - 2015
Figure 9-3: Japan Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs,
and Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
LIST OF FIGURES
Figure 9-4: IND Approval Process in Japan
Figure 9-5: Drug Approval Process in Japan
Figure 9-6: Timeline for Approval of New Drug in Japan
Figure 9-7: Patent Approval Procedure in Japan
Figure 9-8: Australia Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs,
and Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 9-9: Drug Approval Procedure in Australia
Figure 9-10: Patent Approval Procedure in Australia
Figure 9-11: China Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs,
and Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 9-12: Application for Approval of Clinical Study in China
Figure 9-13: Clinical Studies Procedure in China
Figure 9-14: Final Approval Procedure for Drug Registration in China
Figure 9-15: Patent Approval Procedure in China
Figure 9-16: India Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs,
and Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 9-17: New Drug Approval Timeline in India
Figure 9-18: IND Application Procedure in India
Figure 9-19: NDA Approval Procedure in India
Figure 9-20: Patent Approval Procedure in India
Figure 10-1: Porters Five Forces Analysis for Global Anticoagulants Market
Figure 12-1: Financial Performance of Sanofi on the basis of Revenue Generated by Lovenox/
Clexane in USD Million, 2013 2015
Figure 12-2: Financial Performance of Sanofi by Geographical Regions on the basis of
Revenue Contribution by Lovenox/Clexane in terms of Percentages, 2015
Figure 12-3: Financial Performance of Pfizer on the basis of Revenue Generated by Fragmin
in USD Million, 2013 2015
Figure 12-4: Financial Performance of Boehringer Ingelheim on the basis of Revenue
Generated by Pradaxa in USD Million, 2013 2015
Figure 12-5: Financial Performance of Xarelto on the basis of Revenue in USD Million, 2013
2015
Figure 12-6: Financial Performance of Xarelto by Geographical Regions on the basis of
Revenue in USD Million, 2013 2015
Figure 12-7: Financial Performance of Eliquis on the basis of Revenue in USD Million, 2013
 2015
Figure 12-8: Financial Performance of Eliquis by Geographical Regions on the basis of
Revenue in USD Million, 2013 2015
Figure 12-9: Financial Performance of Daichi Sankyo Company on the basis of Revenue
Generated by Edoxaban in USD Million, 2013 2015
Figure 13-1: Global Anticoagulants Market Outlook and Future Projections on the basis of
LIST OF FIGURES
Revenue in USD Million, 2016 2020
Figure 13-2: Global Anticoagulants Market Segmentation Outlook and Future Projections
by Type (Heparin, Novel Oral Anticoagulants, Vitamin K Antagonists, and Injectable Direct
Inhibitors) on the basis of Revenue in Percentage, 2016 - 2020
Figure 13-3: Global Anticoagulants Market Segmentation Outlook and Future Projections
by Geographical Regions (North America, Europe, Asia Pacific, and Rest of the World) on the
basis of Revenue in Percentage, 2016 - 2020
Figure 15-1: Global Aging Population (People Above 65 years) in Millions, 2010 2020
Figure 15-2: Global Number of Deaths from Cardiovascular Diseases in Millions, 2010
2020
Figure 15-3: Global Healthcare Spending in USD Trillion, 2010 2020
Figure 15-4: Global Healthcare Spending by Public and Private Spending in Percentage,
2010 2020
 Table 4-1: Role of Various Stakeholders in the Value Chain of Global Anticoagulants Market
Table 5-1: Global Anticoagulants Market and Rationale for Revenue, 2013 2015
Table 6-1: Global Anticoagulants Market by Type (Heparin, Novel Oral Anticoagulants,
Vitamin K Antagonists, and Injectable Direct Inhibitors) and Rationale for Revenue, 2015
Table 6-2: Comparison of Commonly Prescribed Anticoagulants on the basis of Indication,
Dosing, Route of Administration, Dosage Modifications, and Cost of Treatment
Table 6-3: Global Anticoagulants Market Segmentation by Type (Heparin, Novel Oral
Anticoagulants, Vitamin K Antagonists, and Injectable Direct Inhibitors) on the basis of
LIST OF TABLES

Revenue in USD Million, 2013 - 2015

Table 6-4: Global Heparin Market by Type (Unfractionated and Low Molecular Weight
Heparin) and Rationale for Revenue, 2015
Table 6-5: Key Heparin Drugs and their Generic Name, Route of Administration and Price
Table 6-6: Global Heparin Market Segmentation by Type (Unfractionated and Low Molecular
Weight Heparin) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-7: Global NOACs Market by Type (Rivaroxaban, Apixaban, Dabigatran Etexilate,
and Edoxaban) and Rationale for Revenue, 2015
Table 6-8: Comparative Analysis of NOACs on the basis of Bioavailability, Time to Cmax,
Half Life, Drug Interaction Concerns, Adjustment for Renal Function, Other Adjustments,
Bleed Rates, Major or Common Side Effects, Effects on Common Coagulation Labs, Dosing
Frequency and Unique Point
Table 6-9: Rivaroxaban Approval Timeline
Table 6-10: Apixaban Approval Timeline
Table 6-11: Edoxaban Approval Timeline
Table 6-12: Dabigatran Etexilate Approval Timeline
Table 6-13: Patent Expiries of NOACs by Countries
Table 6-14: Global NOACs Market Segmentation by Type (Rivaroxaban, Apixaban,
Dabigatran Etexilate, and Edoxaban) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-15: Global Anticoagulants Market by Route of Administration (Oral and Injectables)
and Rationale for Revenue, 2015
Table 6-16: Global Anticoagulants Market Segmentation by Route of Administration (Oral
and Injectable) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-17: Global Anticoagulants Market by Geographical Regions (North America, Europe,
Asia Pacific and Rest of the World) and Rationale for Revenue, 2013 - 2015
Table 6-18: Global Anticoagulants Market Segmentation by Geographical Regions (North
America, Europe, Asia Pacific and Rest of the World) on the basis of Revenue in USD Million,
2013 - 2015
Table 7-1: Snapshot on North America Anticoagulants Market
Table 7-2: North America Anticoagulants Market Segmentation by Countries (US and
Canada) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 7-3: Prevalence of Major Disease Indications for which Anticoagulants are used in the
US
Table 7-4: US Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and
Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
 Table 7-5: Key Branded Drugs in the US, Company and their Sales in terms of USD Million,
2013 - 2015
Table 7-6: US Anticoagulants Market Segmentation by Companies (Janssen Pharmaceuticals,
Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, and Others) on the basis of Revenue,
2015
Table 7-7: Drug Approval Applications, Rationale, and Fees in the US, 2016
Table 7-8: Types of Drug Exclusivity, Rationale, and Time Period of Exclusivity
Table 7-9: Prevalence of Major Disease Indications for which Anticoagulants are used in
LIST OF TABLES

Canada
Table 7-10: Canada Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs,
and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 7-11: Key Branded Anticoagulants in Canada, Company and its Average Price
Table 7-12: Market Share of Major Players (Bayer Inc., Boehringer Ingelheim, Bristol Myers
Squibb Canada Co, and Others) in Canada Anticoagulants Market on the basis of Revenue,
2015
Table 7-13: Patent and Exclusivity Procedure in Canada and Rationale
Table 8-1: Prevalence of Major Disease Indications for which Anticoagulants are used in
Europe
Table 8-2: Snapshot on Europe Anticoagulants Market
Table 8-3: Europe Anticoagulants Market Segmentation by Countries (Germany, Spain, Italy,
France, UK, and Rest of the Europe) on the basis of Revenue in terms of USD Million, 2013
- 2015
Table 8-4: Europe Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs,
and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 8-5: Key Branded Anticoagulants in Europe, Company and its Average Price
Table 8-6: Europe Anticoagulants Market Segmentation by Companies (Bayer Inc., Boehringer
Ingelheim, Bristol Myers Squibb, and Others) on the basis of Revenue, 2015
Table 8-7: Product Price Regulation in Europe by Countries, 2016
Table 8-8: Control of Expenditure in Europe by Countries, 2016
Table 8-9: Industry Regulations in Europe by Countries, 2016
Table 8-10: Product Reimbursement in Europe by Countries, 2016
Table 9-1: Snapshot on Asia Pacific Anticoagulants Market
Table 9-2: Asia Pacific Anticoagulants Market Segmentation by Countries (Japan, Australia,
China, India, and Rest of the Asia Pacific) on the basis of Revenue in terms of USD Million,
2013 - 2015
Table 9-3: Prevalence of Major Disease Indications for which Anticoagulants are used in
Japan
Table 9-4: Japan Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and
Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-5: Key Branded Anticoagulants in Japan, and Company
Table 9-6: Prevalence of Major Disease Indications for which Anticoagulants are used in
Australia
 Table 9-7: Australia Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs,
and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-8: Key Branded Anticoagulants in Australia, Company and Average Price in USD
Table 9-9: Prevalence of Major Disease Indications for which Anticoagulants are used in
China
Table 9-10: China Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs,
and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-11: Key Branded Drugs in the China, Company. Price and their Estimated Sales in
LIST OF TABLES

terms of USD Million, 2013 - 2015

Table 9-12: Market Share of Major Players (Bayer Inc., Boehringer Ingelheim, Bristol Myers
Squibb, and Others) in China Anticoagulants Market on the basis of Revenue, 2015
Table 9-13: Prevalence of Major Disease Indications for which Anticoagulants are used in
India
Table 9-14: India Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs,
and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-15: Key Branded Drugs in the India, Company. Price and their Estimated Sales in
terms of USD Million, 2013 - 2015
Table 9-16: Market Share of Major Players (Bayer India, Boehringer Ingelheim, Pfizer, GSK
Pharmaceutical Ltd., Aventis Pharma and Others) in India Anticoagulants Market on the basis
of Revenue, 2015
Table 10-1: Porters Five Forces Analysis for Global Anticoagulants Market
Table 12-1: Global Anticoagulants Market by Manufacturers and Rationale for Revenue,
2015
Table 12-2: Market Share of Major Players (Bayer AG, Boehringer Ingelheim, Bristol-
Myers Squibb Company, Sanofi, Pfizer Inc., Janssen Pharmaceuticals and Others) in Global
Anticoagulants Market on the Basis of Revenue, 2015
Table 12-3: Competitive Landscape of Sanofi including Company Overview, Global
Footprints, Product Portfolio, Business Strategies, Number of Employees, and Key Personnel
Table 12-4: Competitive Landscape of Pfizer Inc. including Company Overview, Global
Footprints, Product Portfolio, Business Strategies, Research and Development, Number of
Employees, and Key Personnel
Table 12-5: Company Profile of Boehringer Ingelheim including Company Overview, Global
Footprints, Business Strategies, and Number of Employees
Table 12-6: Company Profile of Bayer AG including Company Overview, Global Footprints,
Business Strategies, and Number of Employees
Table 12-7: Company Profile of Bristol-Myers Squibb Company including Company Overview,
Global Footprints, Business Strategies, and Number of Employees
Table 12-8: Company Profile of Daichi Sankyo Company, Limited including Company
Overview, Global Footprints, Business Strategies, and Number of Employees
Table 13-1: Future Drivers for Global Anticoagulants Market
Table 13-2: Global Anticoagulants Market Segmentation Outlook and Future Projections
by Type (Heparin, Novel Oral Anticoagulants, Vitamin K Antagonists, and Injectable Direct
Inhibitors) on the basis of Revenue in USD Million, 2016 - 2020
 Table 13-3: Global Anticoagulants Market Segmentation Outlook and Future Projections by
Geographical Regions (North America, Europe, Asia Pacific, and Rest of the World) on the
basis of Revenue in USD Million, 2016 - 2020
Table 14-1: Recommendations for Global Anticoagulants Market
Table 15-1: Rationale for Global Aging Population, 2010 2020
Table 15-2: Rationale for Global Deaths from Cardiovascular Diseases, 2010 2020
Table 15-3: Rationale for Global Healthcare Spending, 2010 2020
LIST OF TABLES
12 Global Anticoagulants Market Outlook to 2020
WHAT IS THE POTENTIAL OF GLOBAL ANTICOAGULANTS
MARKET?
Anticoagulants are defined as the
class of drugs that helps to prevent
blood coagulation or increases the
clotting time. They are also referred as
blood thinners, but these medications
actually dont result in thinning of
blood, instead helps in preventing
the formation of blood clots or breaks
already formed blood clots that
develop in patients blood vessels or in
heart. In absence of treatment, these
clots block the circulation of blood
leading to stroke or heart attack.
As a part of its mechanism,
anticoagulants interfere with the
proteins known as factors, which
are responsible for coagulation
process and disturbs its operations
deteriorating their coagulating
capability, leading to prevention of clot
formation. Anticoagulants sometimes
results in excessive bleeding which
results in harmful effects.
Anticoagulants being the major part
Figure: Global Anticoagulants Market on the basis of Revenue in USD Million, 2013 -
2015
USD Million
2013 2014
Licenses:
Single User: USD 2500
of the first line treatment of heart
diseases including atrial fibrillation, Hard Copy: USD 3000
deep vein thrombosis, pulmonary Enterprise wide: USD 5000
embolism, and stroke have been Pages: 159
used extensively across the globe.
Moreover, growing prevalence of Related Reports
coagulation disorders coupled with Asia Oncology Drug
the aging population has increased Market Outlook to
the demand for anticoagulant drugs 2019 - Driven by Rising
consequently leading to increased Demand and Intensifying
revenue generation. Launch of four Joint Ventures between
patented drugs in the market in newly Companies
formed anticoagulants drug class, The US Anti Cancer Drug
novel oral anticoagulants (NOACs) Market Outlook to 2018 -
in between 2008 and 2014 has also Demand of Oral Drugs to
resulted in high revenue generation Drive Growth
for the total anticoagulants market
as patented drugs are expensive in Global Glaucoma
nature. Global anticoagulants market Treatment Drugs Market
has been valued at USD ~ million Forecast to 2020 -
in 2013 which increased to USD ~ New Product Launches
million in 2015, exhibiting a CAGR of Expected to Boost Market
~% in between 2013 and 2015.
Key Highlights of the
Report
- Discussed leading
players, profile
- Industry statistics from
2013 to 2015 and
forecast from 2016 to
2017
- Discussion on NOACs
Approval and Patent
Expiries
- Snapshot on North
America, Europe and Asia
Pacific Anticoagulants
Market
- Comparative Analysis of
Patented NOACs
2015
Licensed product of Ken Research; should not be copied
13 Global Anticoagulants Market Outlook to 2020

WHAT IS THE SCENARIO OF ASIA PACIFIC REGION IN CONTEXT TO ANTICOAGULANTS

MARKET?
The snapshot on Asia Pacific anticoagulants market
included in study discusses about four major markets
in the region including India, Australia, China, and
Japan. India though generated very low revenue of
USD ~ million in 2015 is expected to grow at a high
pace during the forecast period. High prevalence
of heart disorders in the country coupled with rising
awareness is expected to fuel the anticoagulants
market in India. However, demand for low priced
heparin over expensive NOACs has also resulted
in low revenue contribution from India towards
global market. Among market players, Bayer India
dominated the market with revenue share of ~% in
2015 followed by Pfizer, which contributed 6.8% in
the total revenue.
Table: India Anticoagulants Market Segmentation by Generic
Companies on the Basis of Revenues in Percentage (%), 2015
Particulars % Share
Bayer India ~
Pfizer ~ on the Basis of Revenues in Percentage (%), 2015
Boehringer Ingelheim ~
Aventis Pharma ~ Particulars
Others ~
Total ~
Japan with high awareness and disease prevalence
contributed maximum revenue share (~%) in the
Asia Pacific anticoagulants market, generating
revenue of USD ~ million.
Australia and China are observed to capture second
and third position in the market with revenue shares of
~% and ~% in 2015 respectively.
By types of anticoagulants, heparins have been
observed to dominate the market owing to their less
cost and awareness among the people in the nation.
Especially in China, large numbers of generic heparin
manufacturers are available. These manufacturers
provide heparin sodium and low molecular weight in
very low price, which results in high consumption of the
drug, leading to high revenue generation. Additionally,
presence of generic manufacturers had also increased
the awareness level about heparin among the
healthcare professionals, further spurring its market.
In NOACs segment, only Xarelto and Pradaxa have
existence in the market and the drugs are observed to
generate USD ~ million of revenue in 2015, providing
dominance to Bayer China and Boehringer Ingelheim.
Table: China Anticoagulants Market Segmentation by Type
% Share
Heparin ~
NOACs ~
Injectable Direct ~
Inhibitors
Vitamin K Antagonists ~
Total ~

Licensed product of Ken Research; should not be copied

14 Asia Large Appliances Market Outlook to 2020

HOW RISING PREVALENCE OF DVT/PE IS GOING TO IMPACT GLOBAL ANTICOAGULANTS MARKET?

High incidence rate of DVT and PE globally, leading to large patient population and anticoagulants being an important
part of the first-line treatment has observed a high growth in between 2013 and 2015. It has been estimated that
approximately ~ people get affected by DVT/PE in the US every year. Similarly, it has been observed that there were
~ deaths in UK due to PE in year 2012, which accounts for ~~% of total deaths in UK. Moreover, ~ cases of PE
were reported in UK in one year of period in between 2013 and 2014. The annual incidence of PE is also observed
high in Scandinavia and Australia with estimated value of ~ cases per 1,000 population and ~ cases per 1,000
people respectively. The number is even expected to increase during the forecast period, which will consequently
result in high demand for anticoagulants for treatment purpose, hence driving the market. In addition to this
high prevalence of other heart diseases which involve use of anticoagulants is also fuelling the anticoagulants
market.
HOW PATENTE EXPIRIES OF TWO MAJOR DRUGS IS GOING TO IMPACT ANTICOAGULANTS
MARKET DURING THE FORECAST PERIOD?
Anticoagulants market is expected to grow at a high pace during the forecast period with a projected
CAGR of ~% in between 2016 and 2018. The growth in the forecasted period is estimated lower than
the growth in the historical period owing to the fact that Pradaxa is set to expire in year ~ in major
geographies including US, Japan, and Canada. This would result in launch of generic drugs in the
market, which would result in decreased sales of Pradaxa and other NOACs, resulting in decline
in sales. However, the launch of Praxbind, antidote of Pradaxa in October 2015 will increase the
sales of NOACs in 2016 and 2017, resulting in high growth in the particular years. In long term
scenario, major revenue generating drug in the market Xarelto is set to expire in few countries
including Germany, Japan, China, and Canada in ~, which will further restrain the market
resulting in lower growth in the NOACs segment owing to introduction of generics in the
market. Asia Pacific region is expected to record the highest growth during the forecasted
period majorly due to large presence of patient pool in the market.
Table: Prevalence of Major Disease Indications for which Anticoagulants are Used

Indication Prevalence Statistics

Atrial Fibrillation ~
Coronary Artery Disease ~
Stroke ~
Myocardial Infraction ~
DVT/PE ~

Figure: Anticoagulants Market Future Outlook and Projections on the basis of

Revenue in USD Million, 2016 2020
USD Million

2016 2017 2018 2019 2020

Licensed product of Ken Research; should not be copied

15 Asia Large Appliances Market Outlook to 2020

COMPANIES CITED IN THE REPORT

Companies Covered in the Report List of Companies

Pfizer, Inc.
Sanofi
Boehringer Ingelheim
Major Players Bayer AG
Bristol-Myers Squibb Company
Daichi Sankyo Company, Limited
Janssen Pharmaceuticals

KEY FACTORS CONSIDERED IN THE REPORT

The market size of Global Anticoagulants Market

Market segmentation of Global Anticoagulants Market on the basis of Type, Route of
Administration, and Geographical Analysis
Snapshot on North America Anticoagulants Market
Snapshot on Europe Anticoagulants Market
Snapshot on Asia Pacific Anticoagulants Market
Porters Five Forces Analysis for Global Anticoagulants Market
Trends and Developments in Global Anticoagulants Market
NOACs Drug Approval Timeline
NOACs Patent Expiries
Competitive Landscape and Detailed Company Profiles of the Major Market Players
Future Outlook and Projections of Global Anticoagulants Market
Analyst Recommendations
Macro-Economic Factors Impacting the Global Anticoagulants Market

Licensed product of Ken Research; should not be copied

16

DISCLAIMER

The research reports provided by Ken Research are for the personal information of the authorized
recipient and is not for public distribution and should not be reproduced or redistributed without
prior permission. None of this material may be used for any commercial or public use until unless
authorized by Ken Research. The report will only be used as per the license rights authorized by Ken
Research.
The information provided in the research documents is from publicly available data and other sources,
which are reliable. Efforts are made to try and ensure accuracy of data. With respect to documents
available, neither the company nor any of its employees makes any warranty, express or implied,
including the warranties of merchantability and fitness for a particular purpose, or assumes any legal
liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus,
product, or process disclosed, or represents that its use will not infringe privately owned rights.
The report also includes analysis and views expressed by our research team. The research reports
are purely for information purposes. The opinions expressed are our current opinions as of the date
appearing in the material and may be subject to change from time to time without notice. Investors
should not solely rely on the information contained in the research documents and must make
investment decisions based on their own investment objectives, risk profile and financial position. The
recipients of this material should take their own professional advice before acting on this information.
Ken Research will not accept return of reports once dispatched due to the confidentiality of information
provided in our reports. In case, a report qualify for return, we will issue a credit, minus shipping
charges, of equal value to the original purchase price, toward a future purchaseno refunds. The
decision about whether the product return can be accepted or not is solely at our discretion. Any
dispute will be subject to laws of India and exclusive jurisdiction of Indian Courts

No part of this manual or any material appearing may be reproduced, stored in or transmitted on
any other Web site without written permission of Ken Research and any payments of a specified fee.
Requests to republish any material may be sent to us.

Licensed product of Ken Research; should not be copied

17

CONTACT US

Ken Research Private Limited, 2017. All rights reserved.

For information or permission to reprint, please contact Ken Research at:
Email: query@kenresearch.com
Mail: Ken Research Private Limited
27A, Ground Floor, Spaze I Techpark,
Sector 49, Sohna Road Gurgaon 122001,India
To find latest content or related reports on the sector, please register at www.kenresearch.
com
Follow Ken Research on Linkedin, Facebook and Twitter

Licensed product of Ken Research; should not be copied